Health and Healthcare

Pfizer : PFE

All Pfizer Articles

1508 Articles

Chris Lange | Nov 6, 2018 at 11:50 AM EST

Nektar Therapeutics and Pfizer Team Up in Cancer Collaboration

Nektar shares dipped on Tuesday after the company announced that it would be collaborating with Pfizer to evaluate several combination…

Paul Ausick | Nov 2, 2018 at 4:01 PM EDT

Apple, Intel Tank the Dow Friday

Apple, Intel, Pfizer, and Merck were the worst performing Dow stocks on Friday.

Jon C. Ogg | Nov 1, 2018 at 8:55 AM EDT

Top Analyst Upgrades and Downgrades: American Eagle, Facebook, Nutrisystem, Pfizer, Roku, SeaWorld, Valero, Zynga and More

The top analyst upgrades, downgrades and initiations seen on Thursday included American Eagle Outfitters, Facebook, Nutrisystem, Pfizer, Roku, SeaWorld, Valero…

Chris Lange | Oct 30, 2018 at 8:40 AM EDT

Why Pfizer Is Tripping Over Itself With Earnings

Pfizer reported mixed quarterly results before the markets opened on Tuesday and shares retreated in the premarket.

Chris Lange | Oct 29, 2018 at 11:25 AM EDT

What to Watch For When Pfizer Reports Tuesday Morning

Pfizer is scheduled to release its third-quarter financial results before the markets open on Tuesday.

Chris Lange | Oct 28, 2018 at 7:20 AM EDT

Apple, Exxon, Pfizer and More Dow Earnings to Watch For

24/7 Wall St. has put together a preview of the Dow companies scheduled to report their quarterly results this week.…

Chris Lange | Oct 25, 2018 at 9:00 AM EDT

Major Pharma Short Sellers Hike Their Bets

The October 15 short interest data have been compared with the previous figures, and short interest in most of these…

Lee Jackson | Oct 25, 2018 at 7:10 AM EDT

Why Large Cap Pharmaceuticals Will Hold Up in a Bear Market

These four top pharmaceutical companies have longstanding franchises with huge sales and revenues, and their dividend-paying stocks look like outstanding choices…

Chris Lange | Oct 23, 2018 at 1:15 PM EDT

Pfizer and Bain Capital Partner Up to Tackle CNS Disorders

Pfizer, in collaboration with Bain Capital, announced the creation of Cerevel Therapeutics, a new biopharmaceutical company focused on developing drug…

Paul Ausick | Oct 20, 2018 at 8:55 AM EDT

Apple Again Top-Performing Dow Stock, but Merck Is Closing In

Apple shares dipped again last week, but the company managed to hold onto its rank as the top-performing Dow stock…

Paul Ausick | Oct 14, 2018 at 9:05 AM EDT

9 Dow Components Up by Double Digits

In 2017, 20 of the 30 stocks that comprise the Dow Jones Industrial Average posted double-digit, year-over-year share price gains.…

Paul Ausick | Oct 11, 2018 at 4:01 PM EDT

Chevron, Exxon Hammer the Dow Thursday

For the second consecutive trading day, all 30 Dow stocks closed lower Thursday. Exxon, Chevron, Pfizer, and McDonald's were the…

Chris Lange | Oct 10, 2018 at 9:10 AM EDT

Short Sellers Run for Cover From Major Pharma

The September 28 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical…

Chris Lange | Oct 1, 2018 at 11:50 AM EDT

Pfizer Announces Big Changes at the Top

Pfizer shares hit multiyear highs and nearly an all-time in Monday’s session after the pharma giant announced a succession plan…

Chris Lange | Sep 26, 2018 at 8:50 AM EDT

Short Sellers Grow More Selective on Major Pharma Stocks

The September 14 short interest data have been compared with the previous figures, and short interest moves in these selected…

1 … 33 34 35 36 37 … 101

Pfizer : PFE

All Pfizer Articles

Nektar Therapeutics and Pfizer Team Up in Cancer Collaboration

Apple, Intel Tank the Dow Friday

Top Analyst Upgrades and Downgrades: American Eagle, Facebook, Nutrisystem, Pfizer, Roku, SeaWorld, Valero, Zynga and More

Why Pfizer Is Tripping Over Itself With Earnings

What to Watch For When Pfizer Reports Tuesday Morning

Apple, Exxon, Pfizer and More Dow Earnings to Watch For

Major Pharma Short Sellers Hike Their Bets

Why Large Cap Pharmaceuticals Will Hold Up in a Bear Market

Pfizer and Bain Capital Partner Up to Tackle CNS Disorders

Apple Again Top-Performing Dow Stock, but Merck Is Closing In

9 Dow Components Up by Double Digits

Chevron, Exxon Hammer the Dow Thursday

Short Sellers Run for Cover From Major Pharma

Pfizer Announces Big Changes at the Top

Short Sellers Grow More Selective on Major Pharma Stocks

Why Age 63 Is the Most Expensive Year to Touch Your IRA (Medicare Looks Back Two Years)

PepsiCo’s $200 Billion Stability Play Is Attracting Dividend Investors

Vodafone Group Spikes 13%: Here’s the Story

Why Age 63 Is the Most Expensive Year to Touch Your IRA (Medicare Looks Back Two Years)

"100 Million Percent Wrong" Suze Orman Rages At Social Security Expert's "Crazy" Advice

Why Age 63 Is the Most Expensive Year to Touch Your IRA (Medicare Looks Back Two Years)

PepsiCo’s $200 Billion Stability Play Is Attracting Dividend Investors

Pfizer : PFE

All Pfizer Articles

Nektar Therapeutics and Pfizer Team Up in Cancer Collaboration

Apple, Intel Tank the Dow Friday

Top Analyst Upgrades and Downgrades: American Eagle, Facebook, Nutrisystem, Pfizer, Roku, SeaWorld, Valero, Zynga and More

Why Pfizer Is Tripping Over Itself With Earnings

What to Watch For When Pfizer Reports Tuesday Morning

Apple, Exxon, Pfizer and More Dow Earnings to Watch For

Major Pharma Short Sellers Hike Their Bets

Why Large Cap Pharmaceuticals Will Hold Up in a Bear Market

Pfizer and Bain Capital Partner Up to Tackle CNS Disorders

Apple Again Top-Performing Dow Stock, but Merck Is Closing In

9 Dow Components Up by Double Digits

Chevron, Exxon Hammer the Dow Thursday

Short Sellers Run for Cover From Major Pharma

Pfizer Announces Big Changes at the Top

Short Sellers Grow More Selective on Major Pharma Stocks

Why Age 63 Is the Most Expensive Year to Touch Your IRA (Medicare Looks Back Two Years)

PepsiCo’s $200 Billion Stability Play Is Attracting Dividend Investors

Vodafone Group Spikes 13%: Here’s the Story

Featured Reads

Why Age 63 Is the Most Expensive Year to Touch Your IRA (Medicare Looks Back Two Years)

"100 Million Percent Wrong" Suze Orman Rages At Social Security Expert's "Crazy" Advice